Eledon Pharmaceuticals (ELDN) News Today → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free ELDN Stock Alerts $2.80 +0.29 (+11.55%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 5:34 AM | americanbankingnews.comHC Wainwright Comments on Eledon Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:ELDN)May 11, 2024 | americanbankingnews.comEledon Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.35) Per Share, HC Wainwright Forecasts (NASDAQ:ELDN)May 10, 2024 | markets.businessinsider.comEledon Pharmaceuticals’ Tegoprubart Shows Promising Trial Results and Fuels Buy RatingMay 10, 2024 | americanbankingnews.comHC Wainwright Weighs in on Eledon Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ELDN)May 9, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comEledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comEledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressMay 9, 2024 | marketbeat.comBrokers Issue Forecasts for Eledon Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ELDN)Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - HC Wainwright issued their Q2 2024 EPS estimates for Eledon Pharmaceuticals in a research note issued on Tuesday, May 7th. HC Wainwright analyst V. Bernardino forecasts that the company will post earnings per share of ($0.32) for the quarMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)May 8, 2024 | americanbankingnews.comEledon Pharmaceuticals (NASDAQ:ELDN) Price Target Raised to $16.00 at HC WainwrightMay 7, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionMay 7, 2024 | markets.businessinsider.comEledon Pharmaceuticals’ Tegoprubart Shows Promising Clinical Advancements, Reinforcing Buy Rating and Elevated Price TargetMay 7, 2024 | msn.comNano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased ConfidenceMay 7, 2024 | marketbeat.comEledon Pharmaceuticals (NASDAQ:ELDN) Price Target Increased to $16.00 by Analysts at HC WainwrightHC Wainwright boosted their target price on shares of Eledon Pharmaceuticals from $13.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday.May 7, 2024 | finance.yahoo.comEledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementMay 7, 2024 | globenewswire.comEledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionApril 29, 2024 | msn.com2 Penny Stocks That Wall Street Predicts Will Soar Over 300%March 29, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsMarch 29, 2024 | msn.comELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023March 28, 2024 | globenewswire.comEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsMarch 25, 2024 | globenewswire.comEledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionMarch 25, 2024 | markets.businessinsider.comEledon Pharmaceuticals’ Tegoprubart Shows Best-in-Class Potential in Organ TransplantationMarch 21, 2024 | msn.comKidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To ReceiveMarch 21, 2024 | finance.yahoo.comEledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a HumanFebruary 19, 2024 | finance.yahoo.comEledon Pharmaceuticals, Inc. (ELDN)February 17, 2024 | morningstar.comEledon Pharmaceuticals Inc ELDNFebruary 13, 2024 | globenewswire.comEledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 5, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookJanuary 5, 2024 | msn.comEledon Pharmaceuticals reports recent business milestonesJanuary 4, 2024 | finance.yahoo.comEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookDecember 25, 2023 | finance.yahoo.comWill Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?November 29, 2023 | finance.yahoo.comEledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceNovember 10, 2023 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNovember 9, 2023 | msn.comEledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?November 9, 2023 | finance.yahoo.comEledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNovember 8, 2023 | finance.yahoo.comEledon Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNovember 6, 2023 | markets.businessinsider.comPromising Results and Buy Rating for Eledon Pharmaceuticals: Tegoprubart’s Potential in Kidney Transplant TherapyNovember 4, 2023 | markets.businessinsider.comPromising Phase Ib Study Results Bolster Buy Rating for Eledon Pharmaceuticals: An Analysis by Rami KatkhudaNovember 2, 2023 | finance.yahoo.comEledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationOctober 24, 2023 | msn.comHC Wainwright & Co. Maintains Eledon Pharmaceuticals (ELDN) Buy RecommendationOctober 23, 2023 | msn.comEledon Pharmaceuticals appoints Eliezer Katz as CMOOctober 23, 2023 | markets.businessinsider.comEledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical OfficerOctober 23, 2023 | finance.yahoo.comEledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical OfficerOctober 13, 2023 | finance.yahoo.comEledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual MeetingOctober 2, 2023 | finance.yahoo.comEledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of DirectorsSeptember 28, 2023 | nasdaq.comNoble Capital Markets Initiates Coverage of Eledon Pharmaceuticals (ELDN) with Outperform RecommendationSeptember 27, 2023 | markets.businessinsider.comPromising Clinical Trials and Future Projections Bolster Buy Rating for Eledon PharmaceuticalsSeptember 25, 2023 | finance.yahoo.comEledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a HumanSeptember 20, 2023 | finance.yahoo.comEledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 6, 2023 | finance.yahoo.comEledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Is Gold On a MASSIVE rally? (Ad)Gold has been on a tear this year. The yellow metal has hit an all-time high of $2,4231.29 recently and the rally could be far from over. From central banks to even Costco customers, it seems everyone is buying gold these days. With Wall Street watching the gold space carefully, now is a perfect time to pay attention to this stock. This Little known Company is a uniquely structured for profit ELDN Media Mentions By Week ELDN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELDN News Sentiment▼0.730.55▲Average Medical News Sentiment ELDN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELDN Articles This Week▼151▲ELDN Articles Average Week Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BLRX News Today CELU News Today RPHM News Today ANVS News Today IMMX News Today CALC News Today GANX News Today AEON News Today CKPT News Today AADI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELDN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
